- Advertise
- Contact Us
- Contribute
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
- About Us
© 2022 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
Cushing's Syndrome
The Endocrinology Network® Cushing Disease clinical resource center is a hub for the latest in the management and diagnosis of Cushing’s syndrome. Often referred to as hypercortisolism, this page will host content including articles, videos, podcasts, and clinician-authored columns.
Withdrawal Study Details Effects of Levoketoconazole in Cushing's Syndrome
May 12, 2022
Data presented at AACE 2022 detail levoketoconazole-specific effects observed among patients with endogenous Cushing's syndrome from the phase 3 LOGICS trial.
Increased Risk of Death in Cushing's Disease Persists After Remission
March 23, 2022
An analysis of nationwide data from Sweden provides an overview of the increased risk of death associated with Cushing's disease was present even after biochemical remission.
Mild Autonomous Cortisol Secretion Linked to Increased Hypertension, Requiring Insulin Therapy
January 06, 2022
A cross-sectional study of more than 1000 patients suggests presence of MACS in patients with benign adrenal tumors was associated with increased prevalence and severity of hypertension as well as an increase in the likelihood of requiring insulin therapy in type 2 diabetes.
Levoketoconazole (Recorlev) Receives FDA Approval for Endogenous Cushing's Syndrome
January 04, 2022
Announced on December 30, the approval of levoketoconazole (Recorlev), a cortisol synthesis inhibitor, is for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative.
Study Details Impact of Curative Treatment on Hyperglycemia in Cushing Syndrome
December 14, 2021
A retrospective analysis of data from more than 170 patients with Cushing syndrome and hyperglycemia provides insight into the effects of curative treatment on hyperglycemia among these patients.
More Gradual Dose Titration Could Reduce Hypocortisolism Risk with Osilodrostat in Cushing's Disease
May 28, 2021
Data from LINC3 and LINC4 provide insight into the impact of dosing titration schedules on risk of hypocortisolism-related adverse events associated with osilodrostat use in patients with Cushing's disease.
Osilodrostat and Treatment of Cushing's Disease
November 02, 2020
Georgiana Dobri, MD, a neuroendocrinologist from Weill Cornell Medicine, discusses the approval of osilodrostat and management of Cushing's disease in 2020.
Phase Three Study Demonstrates Promising New Treatment for Cushing’s Syndrome
May 01, 2019
Study of levoketoconazole for Cushing’s syndrome shows significant improvements in acne, hirsutism in women, and peripheral edema.